Tauriga Sciences, Inc. Introduces Its Rainbow Deluxe Sampler Pack - Special Price: $99.99
June 15 2020 - 8:31AM
InvestorsHub NewsWire
The Rainbow Deluxe Sampler
Pack will be Available Exclusively on the Company’s E-Commerce
Website and is Comprised of One Blister Pack of Each Tauri-Gum™
Flavor
Pomegranate (red), Blood Orange (orange),
Peach-Lemon (yellow), Pear Bellini (green), Mint (blue), Black
Currant (purple)
NEW YORK, NY -- June 15, 2020 -- InvestorsHub NewsWire
-- Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (versions: infused with CBD, CBG, Vitamin
C & Zinc) and edibles product(s) as well as two ongoing
Biotechnology initiatives, today introduced its innovative and
dynamic new product offering: The Rainbow Deluxe Sampler Pack
(“Rainbow Pack”). The Rainbow Pack is comprised of one blister pack
of each Tauri-Gum™ flavor (6 blister packs in total) and will be
available exclusively on the Company’s E-Commerce website (www.taurigum.com). Three of the
Tauri-Gum™ flavors are Cannabidiol (“CBD”) infused (Mint, Blood
Orange, Pomegranate), two of the Tauri-Gum™ flavors are
Cannabigerol (“CBG”) infused (Peach-Lemon, Black Currant), and one
Tauri-Gum™ flavor is Vitamin C + Zinc (“Immune Booster”) infused
(Pear Bellini).
The Company anticipates that the Rainbow Pack will be
available on its E-Commerce website during the 1st half of July
2020. The Company continues to experience overall strength in its
E-Commerce business segment and is hopeful that the introduction of
the Rainbow Pack will drive revenue growth next quarter and
beyond.
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol (“CBD”) and
Cannabigerol (“CBG”) Edibles market segment. The main product
line, branded as Tauri-Gum™, consists of a proprietary supplement
chewing gum that is both Kosher certified and Vegan formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) &
(CBG Infused Tauri-Gum™ Flavors: Peach-Lemon and Black Currant).
The Company’s commercialization strategy consists of a broad array
of retail customers, distributors, and a fast-growing E-Commerce
business segment (E-Commerce website: www.taurigum.com).
Please visit our corporate website, for additional information, as
well as inquiries, at www.tauriga.com.
Complementary to the Company’s retail business, are its
two ongoing biotechnology initiatives. The first one relates
to the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On March
18, 2020, the Company announced that it filed a provisional U.S.
patent application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration
agreement with Aegea Biotechnologies Inc. for the co-development of
a rapid, multiplexed, Novel Coronavirus (COVID-19) test with
superior sensitivity and selectivity.
The
Company is headquartered in New York City and operates a regional
office in Barcelona, Spain. In addition, the Company operates
a full-time E-Commerce fulfillment center located in LaGrangeville,
New York.
DISCLAIMER -- Forward-Looking
Statements
This
press release contains certain “forward-looking statements” as
defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward-looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
Cell # (917) 796 9926
Instagram: @taurigu
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024